LGVN Earnings

LGVN reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 137.00K against an estimate of 285.00K, resulting in a -51.87% surprise. The EPS was -0.39, surpassing the expected -0.25 by -56% . The stock experienced a -4.75% price change on the earnings day and a -7.3% change over the next five days, reflecting market reactions to the results.

Following LGVN's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by -4.75% on the day of the release. Over the subsequent five days, it saw a -7.30% change. Historically, LGVN's stock price tends to shift by an average of +13.17% in the 10 days leading up to earnings and -10.56% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate LGVN’s annual revenue to reach 110.00K, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 11.96% and EPS estimates Revise Upward by 134.74% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between LGVN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 11.96%, while EPS estimates moved Revise Upward by 134.74% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LGVN's stock price typically moves by +13.17% in the 10 days before its earnings and -10.56% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 110.00K.

The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.